{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:35:53Z","timestamp":1773930953956,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd013561","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000}}],"reference-count":188,"publisher":"Wiley","issue":"2","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013561.pub2","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T06:44:10Z","timestamp":1707201850000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults"],"prefix":"10.1002","volume":"2024","author":[{"given":"Lisa","family":"Caulley","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology - Head and Neck Surgery; University of Ottawa; Ottawa Canada"},{"name":"Clinical Epidemiology Program; Ottawa Hospital Research Institute; Ottawa Canada"},{"name":"Department of Epidemiology; Erasmus University Medical Center Rotterdam; Rotterdam Netherlands"},{"name":"Institut for Klinisk Medicin; Aarhus University; Aarhus Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason G","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine; Dalhousie University; Halifax Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Anne","family":"Doyle","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program; Ottawa Hospital Research Institute; Ottawa Canada"},{"name":"Endocrinology and Metabolism; University of Ottawa; Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahad","family":"Alkherayf","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology Program; Ottawa Hospital Research Institute; Ottawa Canada"},{"name":"Department of Neurosurgery; University of Ottawa; Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria-Inti","family":"Metzendorf","sequence":"additional","affiliation":[{"name":"Institute of General Practice; Medical Faculty of the Heinrich-Heine University; D\u00fcsseldorf Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaun","family":"Kilty","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology - Head and Neck Surgery; University of Ottawa; Ottawa Canada"},{"name":"Clinical Epidemiology Program; Ottawa Hospital Research Institute; Ottawa Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M G Myriam","family":"Hunink","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics and Department of Radiology and Nuclear Medicine; Erasmus University Medical Center Rotterdam; Rotterdam Netherlands"},{"name":"Center for Health Decision Sciences; Harvard T.H. Chan School of Public Health, Boston; Boston Massachussetts USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD013561.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1055\/s-2001-17910","article-title":"Effectiveness of slow-release lanreotide in previously operated and untreated patients with GH-secreting pituitary macroadenoma","volume":"8","author":"Cannavo","year":"2001","journal-title":"Hormone and Metabolic Research"},{"issue":"5","key":"10.1002\/14651858.CD013561.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao","year":"2009","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0003|cit3","doi-asserted-by":"crossref","unstructured":"Fahlbusch R Kleinberg D Biller B Bonert V Buchfelder M Cappabianca P Surgical debulking of pituitary adenomas improves responsiveness to octreotide LAR in the treatment of acromegaly Pituitary 2017 20 6 668 75","DOI":"10.1007\/s11102-017-0832-8"},{"issue":"8","key":"10.1002\/14651858.CD013561.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1210\/jc.2008-0315","article-title":"Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: a prospective, randomized trial","volume":"93","author":"Carlsen","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-14-0249","article-title":"Preoperative octreotide treatment of acromegaly: long-term results of a randomised controlled trial","volume":"171","author":"Fougner","year":"2014","journal-title":"European Journal of Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s12020-015-0679-6","article-title":"Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response","volume":"51","author":"Helseth","year":"2016","journal-title":"Endocrine"},{"issue":"5","key":"10.1002\/14651858.CD013561.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1111\/j.1365-2265.2011.04106.x","article-title":"Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly","volume":"75","author":"Karaca","year":"2011","journal-title":"Clinical Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1177\/147323001204000213","article-title":"Preoperative lanreotide treatment improves outcome in patients with acromegaly resulting from invasive pituitary macroadenoma","volume":"40","author":"Li","year":"2012","journal-title":"Journal of International Medical Research"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1530\/EJE-09-0908","article-title":"Preoperative lanreotide treatment in acromegalic patients with macroadenomas increases short-term postoperative cure rates: a prospective, randomised trial","volume":"162","author":"Mao","year":"2010","journal-title":"European Journal of Endocrinology"},{"issue":"12","key":"10.1002\/14651858.CD013561.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1507\/endocrj.K10E-203","article-title":"Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study","volume":"57","author":"Shen","year":"2010","journal-title":"Endocrine Journal"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.0300-0664.2001.01438.x","article-title":"Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly","volume":"56","author":"Amato","year":"2002","journal-title":"Clinical Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2265.2007.03067.x","article-title":"A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly","volume":"68","author":"Andries","year":"2008","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12902-016-0096-8","article-title":"Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study","volume":"16","author":"Bronstein","year":"2016","journal-title":"BMC Endocrine Disorders"},{"issue":"10","key":"10.1002\/14651858.CD013561.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1210\/jc.2013-2262","article-title":"Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly","volume":"98","author":"Chieffo","year":"2013","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Colao A Ferone D Marzullo P Di Sarno A Cerbone G Sarnacchiaro F Effect of different dopaminergic agents in the treatment of acromegaly Journal of Clinical Endocrinology and Metabolism 1997 82 2 518 23","DOI":"10.1210\/jcem.82.2.3648"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0016|cit16","article-title":"Phase III, multicenter, randomized study (PAOLA) demonstrating that pasireotide LAR has superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly","volume":"35","author":"Colao","year":"2014","journal-title":"Endocrine Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Colao A Zgliczynski W Komorowski J Kos-Kudla B Tabarin A Kerlan V Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study Endokrynologia Polska 2019 70 4 305 12","DOI":"10.5603\/EP.a2019.0023"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1530\/eje.0.1410267","article-title":"A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly","volume":"141","author":"Cozzi","year":"1999","journal-title":"European Journal of Endocrinology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Ferone D Borson-Chazot F Cailleux A Horsch D Lahner H Pivonello R The novel, ready-to-use octreotide subcutaneous (SC) depot provides higher exposure and maintains response in patients with acromegaly and functioning neuroendocrine tumors (NETs) previously treated with long-acting octreotide: results from a phase 2, open-label, multicenter, randomized study Endocrine Reviews 2017 38 3","DOI":"10.1530\/endoabs.49.GP177"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Ferrari C Romussi M Benco R Rampini P Mailland F Effect of dihydroergocristine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic, and acromegalic subjects: further evidence for pituitary dopamine deficiency in these conditions Acta Endocrinologica (Copenhagen) 1983 103 1 1 6","DOI":"10.1530\/acta.0.1030001"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0022|cit22","doi-asserted-by":"crossref","unstructured":"Fleseriu M Gadelha M Bronstein MD Brue T Coculescu M Guitelman M Pasireotide LAR provides superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly: a phase III, multicenter, randomized study (PAOLA) Growth Hormone & IGF Research 2014 24 S20 S21","DOI":"10.1016\/S1096-6374(14)50053-6"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0023|cit23","article-title":"Novel approach to dose optimization of oral octreotide in patients with acromegaly transitioned from injectable somatostatin analogs","volume":"37","author":"Fleseriu","year":"2016","journal-title":"Endocrine Reviews"},{"issue":"12","key":"10.1002\/14651858.CD013561.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1210\/jcem.80.12.8530606","article-title":"Sandostatin LAR in acromegalic patients: a dose-range study","volume":"80","author":"Fl\u00f8gstad","year":"1995","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD013561.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1210\/jcem-71-5-1189","article-title":"Short term treatment of acromegaly with the somatostatin analog octreotide: the first double-blind randomized placebo-controlled study on its effects","volume":"71","author":"Fredstorp","year":"1990","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD013561.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"870","DOI":"10.4158\/EP11388.OR","article-title":"A subcutaneous octreotide hydrogel implant for the treatment of acromegaly","volume":"18","author":"Gadelha","year":"2012","journal-title":"Endocrine Practice"},{"issue":"11","key":"10.1002\/14651858.CD013561.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes & Endocrinology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0028|cit28","article-title":"Biochemical control is maintained with pasireotide LAR in patients with acromegaly: results from the extension of a randomized phase III study (PAOLA)","volume":"36","author":"Gadelha","year":"2015","journal-title":"Endocrine Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0029|cit29","article-title":"Long-acting pasireotide provides clinical benefit in patients with acromegaly: results from a 30-month analysis of the phase 3 PAOLA study","volume":"38","author":"Gadelha","year":"2017","journal-title":"Endocrine Reviews"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3389\/fendo.2019.00931","article-title":"Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs","volume":"10","author":"Gadelha","year":"2019","journal-title":"Frontiers in Endocrinology"},{"issue":"11","key":"10.1002\/14651858.CD013561.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/BF03345774","article-title":"Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naive to radiation and medical therapy","volume":"32","author":"Ghigo","year":"2009","journal-title":"Journal of Endocrinological Investigation"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-09-0372","article-title":"High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial","volume":"161","author":"Giustina","year":"2009","journal-title":"European Journal of Endocrinology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0033|cit33","first-page":"OC4.1-","article-title":"High-dose octreotide LAR in patients with acromegaly inadequately controlled by conventional somatostatin analogue therapy: a randomized, controlled trial","volume":"20","author":"Giustina","year":"2010","journal-title":"Endocrine Abstracts"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Giustina A Bonadonna S Bugari G Colao A Cozzi R Cannavo S High-dose octreotide LAR in patients with acromegaly inadequately controlled by conventional somatostatin analogue therapy: a randomized, controlled trial Endocrine Abstracts 2010 20","DOI":"10.1530\/EJE-09-0372"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0035|cit35","first-page":"2454","article-title":"High-dose and high-frequency lanreotide autogel in acromegaly patients inadequately controlled on conventional somatostatin analog therapy: a randomized, open label, multicenter study","volume":"38","author":"Giustina","year":"2017","journal-title":"Endocrine Reviews"},{"issue":"7","key":"10.1002\/14651858.CD013561.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2017-00142","article-title":"High-dose and high-frequency lanreotide autogel in acromegaly: a randomized, multicenter study","volume":"102","author":"Giustina","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD013561.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1210\/jcem-70-5-1254","article-title":"A randomized study of SMS 201-995 versus bromocriptine treatment in acromegaly: clinical and biochemical effects","volume":"70","author":"Halse","year":"1990","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD013561.pub2-BIB0038|cit38","first-page":"2958","article-title":"Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs","volume":"85","author":"Herman-Bonert","year":"2000","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD013561.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"542","DOI":"10.4158\/EP-2017-0195","article-title":"Comparison of cabergoline versus raloxifene add-on therapy to long-acting somatostatin analogue in patients with inadequately controlled acromegaly: a randomized open label clinical trial","volume":"24","author":"Imani","year":"2018","journal-title":"Endocrine Practice"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/02688690701395447","article-title":"Excision of pituitary adenomas: randomized comparison of surgical modalities","volume":"21","author":"Jain","year":"2007","journal-title":"British Journal of Neurosurgery"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0041|cit41","unstructured":"Jaquet P Evidence for dopamine agonists in the treatment of acromegaly Journal of Endocrinology 1997 155 Suppl 1 S59 60"},{"issue":"6","key":"10.1002\/14651858.CD013561.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1046\/j.1365-2265.2000.01168.x","article-title":"Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration","volume":"53","author":"Jenkins","year":"2000","journal-title":"Clinical Endocrinology"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s007010050316","article-title":"Does octreotide treatment improve the surgical results of macro-adenomas in acromegaly? A randomized study","volume":"141","author":"Kristof","year":"1999","journal-title":"Acta Neurochirurgica"},{"issue":"8 Suppl 1","key":"10.1002\/14651858.CD013561.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0026-0495(96)90087-6","article-title":"Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients","volume":"45","author":"Lancranjan","year":"1996","journal-title":"Metabolism: Clinical and Experimental"},{"issue":"24","key":"10.1002\/14651858.CD013561.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJM198106113042402","article-title":"No effect of bromocriptine in acromegaly: a controlled trial","volume":"304","author":"Lindholm","year":"1981","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.clpt.2005.04.003","article-title":"Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly","volume":"78","author":"Ma","year":"2005","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"8","key":"10.1002\/14651858.CD013561.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1210\/jc.2011-0654","article-title":"Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients","volume":"96","author":"Madsen","year":"2011","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1530\/EJE-10-0811","article-title":"Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy","volume":"164","author":"Mazziotti","year":"2011","journal-title":"European Journal of Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed","year":"2010","journal-title":"Pituitary"},{"issue":"10","key":"10.1002\/14651858.CD013561.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1210\/jc.2008-0669","article-title":"Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant","volume":"93","author":"Neggers","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"9","key":"10.1002\/14651858.CD013561.pub2-BIB0051|cit51","first-page":"3034","article-title":"Octreotide as primary therapy for acromegaly","volume":"83","author":"Newman","year":"1998","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Oppizzi G Liuzzi A Chiodini P Dallabonzana D Spelta B Silvestrini F Dopaminergic treatment of acromegaly: different effects on hormone secretion and tumor size Journal of Clinical Endocrinology and Metabolism 1984 58 6 988 92","DOI":"10.1210\/jcem-58-6-988"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00280-018-3734-1","article-title":"Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study","volume":"83","author":"Pavel","year":"2019","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD013561.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1210\/jc.2009-2272","article-title":"Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial","volume":"95","author":"Petersenn","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD013561.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/jcph.326","article-title":"Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study","volume":"54","author":"Petersenn","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0056|cit56","article-title":"Exploratory data evaluating the effect of pasireotide on GH, IGF-1, IGFBP-2, IGFBP-3, HbA1c and glucose in patients with inadequately controlled acromegaly enrolled in a 24-week study (PAOLA)","volume":"35","author":"Schmid","year":"2014","journal-title":"Endocrine Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s12020-016-0895-8","article-title":"Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly","volume":"53","author":"Schmid","year":"2016","journal-title":"Endocrine"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","article-title":"Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant","volume":"87","author":"Sesmilo","year":"2002","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","article-title":"Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study","volume":"18","author":"Sheppard","year":"2015","journal-title":"Pituitary"},{"issue":"9","key":"10.1002\/14651858.CD013561.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0026-0495(92)90031-5","article-title":"Presurgical octreotide treatment in acromegaly","volume":"41","author":"Stevenaert","year":"1992","journal-title":"Metabolism, Clinical and Experimental"},{"issue":"7","key":"10.1002\/14651858.CD013561.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1507\/endocrj.EJ16-0624","article-title":"Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study","volume":"64","author":"Tahara","year":"2017","journal-title":"Endocrine Journal"},{"issue":"16","key":"10.1002\/14651858.CD013561.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","article-title":"A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly","volume":"71","author":"Trainer","year":"2009","journal-title":"Clinical Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1530\/EJE-18-0138","article-title":"A randomised, open-label, parallel group phase 2 study of antisense oligonucleotide therapy in acromegaly","volume":"179","author":"Trainer","year":"2018","journal-title":"European Journal of Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s11102-011-0335-y","article-title":"Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly","volume":"15","author":"Tutuncu","year":"2012","journal-title":"Pituitary"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1365-2265.2005.02322.x","article-title":"The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patients","volume":"63","author":"Van der Hoek","year":"2005","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0067|cit67","first-page":"753","article-title":"18 beta-glycyrrhetinic acid ameliorates the cognitive functions and decreases the recurrence rate of pituitary adenomas patients","volume":"17","author":"Wang","year":"2018","journal-title":"EXCLI Journal"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0068|cit68","first-page":"163","article-title":"A randomized comparison of intranasal and injectable octreotide administration in patients with acromegaly","volume":"75","author":"Weeke","year":"1992","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0069|cit69","first-page":"113","article-title":"Morphological effects of octreotide on growth hormone-producing pituitary adenomas","volume":"79","author":"Ezzat","year":"1994","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1530\/eje.0.1330686","article-title":"In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide","volume":"133","author":"Ezzat","year":"1995","journal-title":"European Journal of Endocrinology"},{"issue":"10","key":"10.1002\/14651858.CD013561.pub2-BIB0071|cit71","first-page":"893","article-title":"Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial","volume":"72","author":"Thapar","year":"1997","journal-title":"Mayo Clinic Proceedings"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0072|cit72","unstructured":"Prospective randomized controlled trial of preoperative SSA treatment of invasive growth hormone pituitary adenoma http:\/\/www.chictr.org.cn\/showproj.aspx?proj=130559"},{"issue":"11","key":"10.1002\/14651858.CD013561.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1210\/jc.2014-2900","article-title":"Surgical interventions and medical treatments in treatment-naive patients with acromegaly: systematic review and meta-analysis","volume":"99","author":"Abu Dabrh","year":"2014","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"8","key":"10.1002\/14651858.CD013561.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"943","DOI":"10.4158\/EP14574.OR","article-title":"Radiotherapy versus radiosurgery in treating patients with acromegaly: a systematic review and meta-analysis","volume":"21","author":"Abu Dabrh","year":"2015","journal-title":"Endocrine Practice"},{"issue":"5","key":"10.1002\/14651858.CD013561.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1530\/EJE-15-0189","article-title":"The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study","volume":"173","author":"Agustsson","year":"2015","journal-title":"European Journal of Endocrinology"},{"issue":"9","key":"10.1002\/14651858.CD013561.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"bvac114","DOI":"10.1210\/jendso\/bvac114","article-title":"Medical Treatment for Patients With Acromegaly","volume":"6","author":"Albarel","year":"2022","journal-title":"Journal of the Endocrine Society"},{"issue":"7382","key":"10.1002\/14651858.CD013561.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/bmj.326.7382.219","article-title":"Interaction revisited: the difference between two estimates","volume":"326","author":"Altman","year":"2003","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD013561.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1136\/jnnp-2012-303194","article-title":"Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis","volume":"84","author":"Ammirati","year":"2013","journal-title":"Journal Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.wneu.2017.08.182","article-title":"Endoscopic transsphenoidal approach for acromegaly with remission rates in 401 patients: 2010 consensus criteria","volume":"108","author":"Anik","year":"2017","journal-title":"World Neurosurgery"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1046\/j.1365-2265.2003.01876.x","article-title":"Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment","volume":"59","author":"Baldelli","year":"2003","journal-title":"Clinical Endocrinology"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1210\/jc.2002-020072","article-title":"Clinical review 154: the role of pharmacotherapy in perioperative management of patients with acromegaly","volume":"88","author":"Ben-Shlomo","year":"2003","journal-title":"Journal of Clinical Endocrinology Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ecl.2007.10.002","article-title":"Acromegaly","volume":"37","author":"Ben-Shlomo","year":"2008","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1530\/eje.1.02079","article-title":"Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis","volume":"154","author":"Biering","year":"2006","journal-title":"European Journal of Endocrinology"},{"issue":"9","key":"10.1002\/14651858.CD013561.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1210\/jc.2008-0833","article-title":"Lipodystrophy in patients with acromegaly receiving pegvisomant","volume":"93","author":"Bonert","year":"2008","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/B978-0-444-59602-4.00011-3","article-title":"Imaging of pituitary pathology","volume":"124","author":"Buchfelder","year":"2014","journal-title":"Handbook of Clinical Neurology"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"e00033","DOI":"10.1002\/edm2.33","article-title":"Diabetes mellitus induced by somatostatin analogue therapy is not permanent in acromegalic patients","volume":"2","author":"Cappellani","year":"2018","journal-title":"Endocrinology, Diabetes and Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0087|cit87","doi-asserted-by":"publisher","first-page":"523\u20137","DOI":"10.1210\/jc.2008-1371","article-title":"The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly","volume":"94","author":"Carmichael","year":"2009","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","article-title":"Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial","volume":"99","author":"Caron","year":"2014","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrendo.2010.4","article-title":"Role of stereotactic radiosurgery in the management of pituitary adenomas","volume":"6","author":"Castinetti","year":"2010","journal-title":"Nature Reviews Endocrinology"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0090|cit90","first-page":"E5","article-title":"Extended endoscopic endonasal approach to the pterygopalatine fossa: anatomical study and clinical considerations","volume":"19","author":"Cavallo","year":"2005","journal-title":"Neurosurgical Focus"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ando.2008.12.011","article-title":"French consensus on the management of acromegaly","volume":"70","author":"Chanson","year":"2009","journal-title":"Annales d'Endocrinologie"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000377704","article-title":"Medical treatment of acromegaly with dopamine agonists or somatostatin analogs","volume":"103","author":"Chanson","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0093|cit93","unstructured":"CENTRAL creation details www.cochranelibrary.com\/central\/central-creation"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocrine Reviews"},{"issue":"7","key":"10.1002\/14651858.CD013561.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1210\/jc.2008-0299","article-title":"Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy","volume":"93","author":"Colao","year":"2008","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0096|cit96","unstructured":"Consolidated Standards of Reporting Trials (CONSORT) The CONSORT statement www.consort-statement.org"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0097|cit97","unstructured":"Deeks JJ Higgins JP Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12020-015-0610-1","article-title":"Long-term results of fractionated stereotactic radiotherapy as third-line treatment in acromegaly","volume":"50","author":"Diallo","year":"2015","journal-title":"Endocrine"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/EJE-09-1080","article-title":"Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines","volume":"163","author":"Dworakowska","year":"2010","journal-title":"European Journal of Endocrinology"},{"issue":"6","key":"10.1002\/14651858.CD013561.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"668","DOI":"10.4158\/EP14575.DSCR","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology Disease State Clinical Review: management of acromegaly patients: what is the role of pre-operative medical therapy?","volume":"21","author":"Fleseriu","year":"2015","journal-title":"Endocrine Practice"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12020-015-0810-8","article-title":"Combined treatment of somatostatin analogues with pegvisomant in acromegaly","volume":"52","author":"Franck","year":"2016","journal-title":"Endocrine"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0104|cit104","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime)"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nrendo.2014.21","article-title":"Expert consensus document: a consensus on the medical treatment of acromegaly","volume":"10","author":"Giustina","year":"2014","journal-title":"Nature Reviews Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12020-015-0766-8","article-title":"Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly","volume":"52","author":"Heck","year":"2016","journal-title":"Endocrine"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0108|cit108","unstructured":"Higgins JP Altman DG Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0109|cit109","unstructured":"Higgins JP Li T Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0110|cit110","unstructured":"Higgins JP Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2265.1992.tb01443.x","article-title":"Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly","volume":"36","author":"Ho","year":"1992","journal-title":"Clinical Endocrinology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"g1687","DOI":"10.1136\/bmj.g1687","article-title":"Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide","volume":"348","author":"Hoffmann","year":"2014","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"j2998","DOI":"10.1136\/bmj.j2998","article-title":"Enhancing the usability of systematic reviews by improving the consideration and description of interventions","volume":"358","author":"Hoffmann","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"European Journal of Endocrinology"},{"issue":"6","key":"10.1002\/14651858.CD013561.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s11102-015-0655-4","article-title":"The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013","volume":"18","author":"Hoskuldsdottir","year":"2015","journal-title":"Pituitary"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0116|cit116","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Medical Research Methodology"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"8","DOI":"10.15605\/jafes.034.01.03","article-title":"Malaysian consensus statement for the diagnosis and management of acromegaly","volume":"34","author":"Hussein","year":"2019","journal-title":"Journal of the ASEAN Federation of Endocrine Societies"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0889-8529(18)30210-X","article-title":"Treatment of acromegaly with dopamine agonists","volume":"21","author":"Jaffe","year":"1992","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/jc.2005-1616","article-title":"Conventional pituitary irradiation is effective in lowering serum growth hormone and insulin-like growth factor-I in patients with acromegaly","volume":"91","author":"Jenkins","year":"2006","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3171\/jns.1997.87.1.0044","article-title":"Endoscopic endonasal transsphenoidal surgery: experience with 50 patients","volume":"87","author":"Jho","year":"1997","journal-title":"Journal of Neurosurgery"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/foc.2005.19.1.9","article-title":"Evolution of reconstructive techniques following endoscopic expanded endonasal approaches","volume":"19","author":"Kassam","year":"2005","journal-title":"Neurosurgical Focus"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0122|cit122","first-page":"E3","article-title":"Expanded endonasal approach: the rostrocaudal axis. Part I. Crista galli to the sella turcica","volume":"19","author":"Kassam","year":"2005","journal-title":"Neurosurgical Focus"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0123|cit123","first-page":"E4","article-title":"Expanded endonasal approach: the rostrocaudal axis. Part II. Posterior clinoids to the foramen magnum","volume":"19","author":"Kassam","year":"2005","journal-title":"Neurosurgical Focus"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.3171\/foc.2005.19.1.7","article-title":"Expanded endonasal approach: fully endoscopic, completely transnasal approach to the middle third of the clivus, petrous bone, middle cranial fossa, and infratemporal fossa","volume":"19","author":"Kassam","year":"2005","journal-title":"Neurosurgical Focus"},{"issue":"1 Suppl","key":"10.1002\/14651858.CD013561.pub2-BIB0125|cit125","first-page":"E213","article-title":"The expanded endonasal approach: a fully endoscopic transnasal approach and resection of the odontoid process: technical case report","volume":"57","author":"Kassam","year":"2005","journal-title":"Neurosurgery"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP.17.S4.1","article-title":"American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly--2011 update","volume":"17 Suppl 4","author":"Katznelson","year":"2011","journal-title":"Endocrine Practice"},{"issue":"11","key":"10.1002\/14651858.CD013561.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","article-title":"Acromegaly: an endocrine society clinical practice guideline","volume":"99","author":"Katznelson","year":"2014","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"c365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0129|cit129","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.wneu.2011.07.011","article-title":"Endoscopic endonasal compared with microscopic transsphenoidal and open transcranial resection of craniopharyngiomas","volume":"77","author":"Komotar","year":"2012","journal-title":"World Neurosurgery"},{"issue":"9","key":"10.1002\/14651858.CD013561.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1210\/jcem.86.9.7819","article-title":"Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria","volume":"86","author":"Kreutzer","year":"2001","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s11102-016-0754-x","article-title":"Epidemiology of acromegaly: review of population studies","volume":"20","author":"Lavrentaki","year":"2016","journal-title":"Pituitary"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1210\/jc.2013-3743","article-title":"Stereotactic radiosurgery for acromegaly","volume":"99","author":"Lee","year":"2014","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD013561.pub2-BIB0133|cit133","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLOS Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013561.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1210\/jc.2011-0251","article-title":"Radiation therapy in the management of pituitary adenomas","volume":"96","author":"Loeffler","year":"2011","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/jrsm.1287","article-title":"Machine learning for identifying randomized controlled trials: an evaluation and practitioner\u2019s guide","volume":"9","author":"Marshall","year":"2018","journal-title":"Research Synthesis Methods"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0136|cit136","unstructured":"McDonald S Noel-Storr AH Thomas J Harnessing the efficiencies of machine learning and Cochrane Crowd to identify randomised trials for individual Cochrane reviews. Global Evidence Summit; 2017 Sept 13-16; Cape Town (South Africa) Cape Town (South Africa) Global Evidence Summit 2017"},{"issue":"24","key":"10.1002\/14651858.CD013561.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013561.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/JCI3937","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10.1002\/14651858.CD013561.pub2-BIB0139|cit139","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1210\/jc.2008-2421","article-title":"Guidelines for acromegaly management: an update","volume":"94","author":"Melmed","year":"2009","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0140|cit140","volume-title":"Williams Textbook of Endocrinology","author":"Melmed","year":"2016"},{"issue":"9","key":"10.1002\/14651858.CD013561.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","article-title":"A Consensus Statement on acromegaly therapeutic outcomes","volume":"14","author":"Melmed","year":"2018","journal-title":"Nature Reviews Endocrinology"},{"issue":"6","key":"10.1002\/14651858.CD013561.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1365-2265.2007.02825.x","article-title":"A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly","volume":"66","author":"Mercado","year":"2007","journal-title":"Clinical Endocrinology"},{"issue":"12","key":"10.1002\/14651858.CD013561.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"5","key":"10.1002\/14651858.CD013561.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1213\/01.ane.0000166976.61650.ae","article-title":"Perioperative management of patients undergoing transsphenoidal pituitary surgery","volume":"101","author":"Nemergut","year":"2005","journal-title":"Anesthesia & Analgesia"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0146|cit146","unstructured":"Noel-Storr AH and the Project Transform team Cochrane Crowd: new ways of working together to produce health evidence. Evidence Live 2018; 2018 Jun 18-20; Oxford (UK) Oxford (UK) Evidence Live 2018"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s11102-014-0602-9","article-title":"Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system","volume":"18","author":"Nunes","year":"2015","journal-title":"Pituitary"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0148|cit148","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.wneu.2016.10.029","article-title":"Endoscopic endonasal versus microsurgical transsphenoidal approach for growth hormone-secreting pituitary adenomas-systematic review and meta-analysis","volume":"97","author":"Phan","year":"2017","journal-title":"World Neurosurgery"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1530\/ERC-14-0305","article-title":"Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences","volume":"22","author":"Potorac","year":"2015","journal-title":"Endocrine-Related Cancer"},{"issue":"11","key":"10.1002\/14651858.CD013561.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1530\/ERC-16-0356","article-title":"T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly","volume":"23","author":"Potorac","year":"2016","journal-title":"Endocrine-Related Cancer"},{"issue":"11","key":"10.1002\/14651858.CD013561.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"4973","DOI":"10.1210\/jc.2010-0573","article-title":"Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure","volume":"95","author":"Puig-Domingo","year":"2010","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"106781","DOI":"10.1016\/j.clineuro.2021.106781","article-title":"Comparative effectiveness of endoscopic versus microscopic transsphenoidal surgery for patients with growth hormone secreting pituitary adenoma: an emulated trial","volume":"207","author":"Qiao","year":"2021","journal-title":"Clinical Neurology and Neurosurgery"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"European Journal of Endocrinology"},{"issue":"22","key":"10.1002\/14651858.CD013561.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3748\/wjg.14.3484","article-title":"Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis","volume":"14","author":"Rokkas","year":"2008","journal-title":"World Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2005-1704","article-title":"Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors","volume":"91","author":"Ronchi","year":"2005","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11102-010-0281-0","article-title":"Frequency of acromegaly in adults with diabetes or glucose intolerance and estimated prevalence in the general population","volume":"14","author":"Rosario","year":"2011","journal-title":"Pituitary"},{"issue":"7","key":"10.1002\/14651858.CD013561.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"483","DOI":"10.4161\/cbt.9.7.11581","article-title":"Growth hormone-secreting pituitary adenomas: from molecular basis to treatment options in acromegaly","volume":"9","author":"Sabino","year":"2010","journal-title":"Cancer Biology and Therapy"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0158|cit158","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11102-012-0460-2","article-title":"Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry","volume":"17","author":"Salvatori","year":"2014","journal-title":"Pituitary"},{"issue":"5","key":"10.1002\/14651858.CD013561.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"11","key":"10.1002\/14651858.CD013561.pub2-BIB0160|cit160","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000005.pub4","article-title":"Full publication of results initially presented in abstracts","author":"Scherer","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00000542-200007000-00020","article-title":"Difficult intubation in acromegalic patients: incidence and predictability","volume":"93","author":"Schmitt","year":"2000","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1530\/EJE-12-0602","article-title":"Long-term outcome in patients with acromegaly: analysis of 1344 patients from the German Acromegaly Register","volume":"168","author":"Sch\u00f6fl","year":"2013","journal-title":"European Journal of Endocrinology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0163|cit163","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Guyatt GH Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/oxfordjournals.bja.a013400","article-title":"Anaesthetic complications of acromegaly","volume":"84","author":"Seidman","year":"2000","journal-title":"British Journal of Anaesthesia"},{"issue":"9","key":"10.1002\/14651858.CD013561.pub2-BIB0165|cit165","doi-asserted-by":"publisher","first-page":"e0183539","DOI":"10.1371\/journal.pone.0183539","article-title":"Prevalence of acromegaly in patients with symptoms of sleep apnea","volume":"12","author":"Sesmilo","year":"2017","journal-title":"PLOS One"},{"issue":"11","key":"10.1002\/14651858.CD013561.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00234-016-1728-4","article-title":"Predictive value of T2 relative signal intensity for response to somatostatin analogs in newly diagnosed acromegaly","volume":"58","author":"Shen","year":"2016","journal-title":"Neuroradiology"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1210\/jc.2008-1420","article-title":"Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues","volume":"94","author":"Sherlock","year":"2009","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0168|cit168","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11154-007-9065-x","article-title":"Radiation therapy in acromegaly","volume":"9","author":"Shih","year":"2008","journal-title":"Reviews in Endocrine and Metabolic Disorders"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD013561.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/S0026-0495(96)90088-8","article-title":"Presurgical octreotide: treatment in acromegaly","volume":"45","author":"Stevenaert","year":"1996","journal-title":"Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/s1043-2760(00)00244-7","article-title":"Current therapy for acromegaly","volume":"11","author":"Stewart","year":"2000","journal-title":"Trends in Endocrinology and Metabolism"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0172|cit172","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1210\/jc.2011-3237","article-title":"Update on pituitary surgery","volume":"97","author":"Swearingen","year":"2012","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"17","key":"10.1002\/14651858.CD013561.pub2-BIB0173|cit173","first-page":"30604","article-title":"Living systematic reviews: 2. combining human and machine effort","volume":"S0895-4356","author":"Thomas","year":"2017","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0174|cit174","doi-asserted-by":"publisher","first-page":"S150","DOI":"10.21037\/gs.2019.06.04","article-title":"Pituitary magnetic resonance imaging predictive role in the therapeutic response of growth hormone-secreting pituitary adenomas","volume":"8 Suppl 3","author":"Tortora","year":"2019","journal-title":"Gland Surgery"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0175|cit175","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1210\/jc.85.3.1159","article-title":"Angiogenesis in pituitary adenomas and the normal pituitary gland","volume":"85","author":"Turner","year":"2000","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"9295","key":"10.1002\/14651858.CD013561.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"Van der Lely","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD013561.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"1589\u201397","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"Van der Lely","year":"2012","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0178|cit178","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11102-016-0772-8","article-title":"Acromegaly: clinical features at diagnosis","volume":"20","author":"Vilar","year":"2017","journal-title":"Pituitary"},{"issue":"9","key":"10.1002\/14651858.CD013561.pub2-BIB0179|cit179","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/alr.21356","article-title":"Significant increases of pituitary tumors and resections from 1993 to 2011","volume":"4","author":"Villwock","year":"2014","journal-title":"International Forum of Allergy and Rhinology"},{"issue":"1","key":"10.1002\/14651858.CD013561.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1042-3680(18)30829-5","article-title":"Role of surgery in the management of pituitary tumors","volume":"1","author":"Wilson","year":"1990","journal-title":"Neurosurgery Clinics of North America"},{"issue":"4","key":"10.1002\/14651858.CD013561.pub2-BIB0181|cit181","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11102-012-0457-x","article-title":"Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications","volume":"16","author":"Wilson","year":"2013","journal-title":"Pituitary"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0182|cit182","first-page":"257","volume-title":"Endocrinology","author":"Witte","year":"2001"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0183|cit183","doi-asserted-by":"publisher","first-page":"e88787","DOI":"10.1371\/journal.pone.0088787","article-title":"Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review","volume":"9","author":"Wolinski","year":"2014","journal-title":"PLOS One"},{"issue":"7644","key":"10.1002\/14651858.CD013561.pub2-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","article-title":"Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study","volume":"336","author":"Wood","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013561.pub2-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"14070","DOI":"10.1038\/s41598-019-50639-6","article-title":"Preoperative somatostatin analogues in patients with newly-diagnosed acromegaly: a systematic review and metaanalysis of comparative studies","volume":"9","author":"Yang","year":"2019","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0186|cit186","first-page":"57","article-title":"Updates in diagnosis and treatment of acromegaly","volume":"14","author":"Zahr","year":"2018","journal-title":"European Endocrinology"},{"issue":"2","key":"10.1002\/14651858.CD013561.pub2-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.braindev.2014.04.009","article-title":"Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis","volume":"37","author":"Zhang","year":"2015","journal-title":"Brain & Development"},{"issue":"3","key":"10.1002\/14651858.CD013561.pub2-BIB0188|cit188","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013561","article-title":"Surgical and non-surgical interventions for primary and salvage treatment of growth hormone-secreting pituitary adenomas in adults","author":"Caulley","year":"2020","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T03:18:07Z","timestamp":1760498287000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013561.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Metabolic and Endocrine Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":188,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013561.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]}}}